AbbVie Inc. (ABBV) operating KPIs
ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026Score 10/3094% above fair value
$294.89+4.10 (+1.41%)
Close on Oct 30, 2026Market cap $521.11BP/E 83.3Yield 2.26%
AbbVie elahere (mirvetuximab soravtansine) — U.S. reported growth YoY (%) (%)
Form 8-K Key Product Revenues Schedule
Latest, Q2 2026
17.1%
Period ended Jun 30, 2026
Change on a year earlier
+9.1 pts
8.0% in Q2 2025
History
5 quarters
Since Q2 2025
Sources
5
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Elahere (mirvetuximab soravtansine) — U.S. reported growth YoY (%) (%) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 17.1% | +9.1 pts | Form 8-K (abbv-20260630xexhibit991.htm, filed 2026-07-31) ↗ |
| Q1 2026 | Mar 31, 2026 | -2.9% | – | Form 8-K (abbv-20260331xexhibit991.htm, filed 2026-04-29) ↗ |
| Q4 2025 | Dec 31, 2025 | 5.0% | – | Form 8-K (abbv-20251231xexhibit991.htm, filed 2026-02-04) ↗ |
| Q3 2025 | Sep 30, 2025 | 8.6% | – | Form 8-K (abbv-20250930xexhibit991.htm, filed 2025-10-31) ↗ |
| Q2 2025 | Jun 30, 2025 | 8.0% | – | Form 8-K (abbv-20250630xexhibit991.htm, filed 2025-07-31) ↗ |
Cite this data
StockData. (2026). AbbVie Elahere (mirvetuximab soravtansine) — U.S. reported growth YoY (%) (%), quarterly Q2 2025–Q2 2026 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/elahere_us_rep_yoy
See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.